BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Michelle M.
MADRID -- Vericiguat (Verquvo) missed the mark for reducing heart failure (HF) hospitalizations but lowered the risk of cardiovascular death in patients with HF with reduced ejection fraction (HFrEF) ...
Good day, and welcome to the TX45 Phase Ib Part B PH-HFrEF data conference call. [Operator Instructions] As a reminder, this call may be recorded. I would now like to turn the call over to Dr. Alise ...
AMSTERDAM, the Netherlands—Among patients with heart failure with reduced ejection fraction (HFrEF), a previously implanted pacemaker or ICD, and a significant RV pacing burden, upgrading to a cardiac ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results